대용 인공 혈액 시장 - 세계 및 지역별 분석 : 용도별, 최종 용도별, 제품별, 유래별, 유형별, 구성별, 지역별 - 분석 및 예측(2024-2034년)

Synthetic Blood Substitute Market - A Global and Regional Analysis: Focus on Application, End-use, Product, Source, Type, Configuration, and Region - Analysis and Forecast, 2024-2034

US $ 5,500 ￦ 7,707,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,400 ￦ 11,771,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

대용 인공 혈액 시장 규모는 기존 수혈의 한계를 극복하기 위한 중요한 솔루션으로 빠르게 부상하고 있으며, 전 세계 다양한 의료 분야에서 광범위하게 적용되고 있습니다.

외상, 수술 및 만성 질환이 증가함에 따라 대용 인공 혈액은 신뢰할 수 있고 안전한 대안을 제공하여 중요한 혈액 성분의 중단없는 공급을 보장합니다. 낙관적인 시나리오에서 2024년 870만 달러로 평가된 시장은 연평균 15.43% 성장하여 2034년에는 3,670만 달러에 달할 것으로 예상됩니다.

의료의 발전과 신뢰할 수 있는 대체 혈액에 대한 요구가 높아지면서 의료 분야에서 대용 인공 혈액에 대한 수요가 증가하고 있습니다. 외상, 수술, 만성질환의 발생률이 지속적으로 증가함에 따라 기존 수혈의 한계를 극복할 수 있는 효과적이고 안전한 대체혈액에 대한 필요성이 증가하고 있습니다. 인공 혈액은 천연 혈액의 산소 운반 및 응고 기능을 모방할 수 있어 응급의료, 수술, 만성질환 관리 등의 분야에서 중요한 솔루션으로 부상하고 있습니다.

주요 시장 통계
예측 기간	2024-2034년
2024년 평가	870만 달러
2034년 전망	3,670만 달러
CAGR	15.43%

대용 인공 혈액 시장에는 높은 연구개발 비용과 규제 당국의 승인에 따른 복잡성 등 여러 가지 어려움이 있습니다. 또한, 다양한 질환에 대한 대체 혈액의 안전성과 유효성을 확보하는 것은 시장 진입과 확장에 더욱 복잡성을 더하고 있습니다. 그러나 이러한 도전은 생명공학 기업, 의료 서비스 제공자 및 규제 기관 간의 혁신과 협력을 촉진하여 보다 진보된 대용 인공 혈액품의 개발을 촉진하고 현대 의학에서 그 잠재적 용도를 확장하고 있습니다.

미국을 필두로 한 북미는 첨단 생물의학 연구 부문과 탄탄한 헬스케어 인프라를 바탕으로 대용 인공 혈액품 시장을 주도하고 있습니다. 미국은 연구개발에 대한 활발한 투자와 규제기관의 강력한 지원으로 대용 인공 혈액품 개발을 선도하고 있습니다. 이러한 환경은 기술 혁신을 촉진하여 외상 치료, 수술 및 만성 질환 관리의 중요한 요구를 충족하는 최첨단 합성 혈액제제를 생산하고 있습니다. 또한, 미국은 의료 성과를 개선하고 혈액 공급 부족 문제를 해결하기 위해 다양한 의료 분야에서 대용 인공 혈액품의 채택을 추진하고 있습니다. 환자 안전과 기술 발전에 중점을 두고 있는 미국에서는 대용 인공 혈액품의 효능과 신뢰성이 지속적으로 개선되고 있습니다. 미국은 의료 서비스를 강화하고 증가하는 인공 혈액 수요를 충족시키는 데 중점을 두면서 세계 인공 혈액 시장의 선두주자로서의 입지를 확고히 하고 있습니다.

이 보고서는 세계 대용 인공 혈액 시장을 조사하여 시장 개요와 함께 용도별, 최종 용도별, 제품별, 유래별, 유형별, 구성별, 지역별 동향, 시장 진입 기업 개요 등을 제공합니다.

목차

주요 요약

제1장 시장 : 업계 전망

• 동향 : 현재 및 향후의 영향 평가
• 공급망 개요
• R&D 리뷰
• 규제 상황
• 이해관계자 분석
• 주요 세계적 이벤트의 영향 분석
• 시장 역학 개요

제2장 대용 인공 혈액 시장(용도별)

• 용도 세분화
• 용도 개요
• 대용 인공 혈액 시장(용도별)
• 대용 인공 혈액 시장(최종 용도별)

제3장 대용 인공 혈액 시장(제품별)

• 제품 세분화
• 제품 개요
• 대용 인공 혈액 시장(제품별)
• 대용 인공 혈액 시장(유래별)
• 대용 인공 혈액 시장(유형별)
• 대용 인공 혈액 시장(구성별)

제4장 대용 인공 혈액 시장(지역별)

• 대용 인공 혈액 시장(지역별)
• 북미
• 유럽
• 아시아태평양
• 기타 지역

제5장 기업 개요

• 향후 전망
• 지리적 평가
• 기업 개요
  • Aurum Biosciences
  • HEMARINA
  • Hemoglobin Oxygen Therapeutics LLC
  • KaloCyte, Inc.
  • Spheritech Ltd
  • VisusMed Medical Center
  • OPKO Health, Inc.
  • NuvOx Pharma
  • Prolong Pharmaceuticals
  • Boston Pharmaceuticals
  • ATPL
  • Baxter
  • Biopharma corp
  • NORTHFIELD LABORATORIES INC.
  • Alliance Pharma PLC
  • 기타 주요 기업

제6장 조사 방법

ksm

영문 목차

영문목차

Introduction to Synthetic Blood Substitute Market

The synthetic blood substitute market is rapidly emerging as a critical solution to address the limitations of traditional blood transfusions, finding widespread applications across various medical fields globally. With increasing incidences of trauma, surgeries, and chronic diseases, synthetic blood substitutes offer a reliable and safe alternative, ensuring an uninterrupted supply of vital blood components. In an optimistic scenario, the market, valued at $8.7 million in 2024, is anticipated to grow at a CAGR of 15.43%, reaching $36.7 million by 2034.

Increasing medical advancements and a growing need for reliable blood alternatives are driving the demand for synthetic blood substitutes in the healthcare sector. As incidences of trauma, surgeries, and chronic diseases continue to rise, there is a growing necessity for effective and safe blood substitutes that can overcome the limitations of traditional blood transfusions. Synthetic blood substitutes, with their ability to mimic the oxygen-carrying and clotting functions of natural blood, have emerged as a critical solution across applications such as emergency medicine, surgeries, and chronic disease management.

KEY MARKET STATISTICS
Forecast Period	2024 - 2034
2024 Evaluation	$8.7 Million
2034 Forecast	$36.7 Million
CAGR	15.43%

In the synthetic blood substitute market, challenges include high research and development costs and the complexities associated with regulatory approvals. Additionally, ensuring the safety and efficacy of these substitutes in diverse medical conditions adds further complexity to market entry and expansion. However, these challenges promotes innovation and collaboration among biotech firms, healthcare providers, and regulatory bodies, driving the development of more advanced synthetic blood substitutes and expanding their potential applications in modern medicine.

North America, led by the U.S., dominates the synthetic blood substitute market, driven by its advanced biomedical research sector and substantial healthcare infrastructure. U.S. leads in synthetic blood substitute development due to its robust investment in research and development, coupled with strong support from regulatory bodies. This environment promotes innovation, resulting in cutting-edge synthetic blood products that address critical needs in trauma care, surgeries, and chronic disease management. Furthermore, the U.S. commitment to improving healthcare outcomes and addressing blood supply shortages propels the adoption of synthetic blood substitutes across various medical fields. The nation's emphasis on patient safety and technological advancements ensures that synthetic blood substitutes are continually refined for efficacy and reliability. With a focus on enhancing medical care and meeting the increasing demand for blood substitutes, the U.S. solidifies its position as a key player in the global synthetic blood substitute market.

Key players such as Aurum Biosciences, HEMARINA, Hemoglobin Oxygen Therapeutics LLC, and KaloCyte, Inc. are at the forefront of market expansion, utilizing their technological expertise and strategic partnerships to drive innovation and capture a significant market share. Companies are investing in the construction of new production facilities and the expansion of existing ones to meet the growing demand. For instance, in September 2022, VirTech Bio received approximately $13.7 million in funding from the Pentagon and the U.S. Department of Defense (DoD) to advance the clinical research of its hemoglobin-based oxygen-carrying solution, OxyBridge. This product is designed to prevent hemorrhagic shock in trauma patients and enhance the viability of organs donated for transplantation.

Market Segmentation:

Segmentation 1: by Application

• Cardiovascular Diseases
• Malignant Neoplasma
• Injuries
• Neonatal Conditions
• Organ Transplant
• Maternal Condition
• Others

Segmentation 2: by End-use

• Hospitals
• Ambulatory Surgical Centers
• Military and Defense
• Research Laboratories
• Emergency Services
• Others

Segmentation 3: by Product

• Hemoglobin-Based Oxygen Carriers (HBOCs)
• Perfluorocarbon Emulsions (PFCs)
• Stem Cell-Derived Red Blood Cells
• Others

Segmentation 4: by Source

• Human Blood
• Microorganism Based Recombinant HB
• Synthetic Polymers
• Stem Cells
• Others

Segmentation 5: by Component

• Red Blood Cell Substitutes
• Platelet Substitutes
• Plasma Substitutes

Segmentation 6: by Configuration

• Injectable Solutions
• Powdered Forms
• Infusion Bags
• Capsules and Tablets
• Others

Segmentation 7: by Region

• North America
• Europe
• Asia-Pacific
• Rest-of-the-World

How can this report add value to an organization?

Product/Innovation Strategy: The global synthetic blood substitute market has been extensively segmented based on various categories, such as application, end-use, product, source, component, and configuration. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: A detailed competitive benchmarking of the players operating in the global synthetic blood substitute market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some of the prominent companies in this market are:

• Aurum Biosciences
• HEMARINA
• Hemoglobin Oxygen Therapeutics LLC
• KaloCyte, Inc.
• Spheritech Ltd
• NuvOx Pharma
• Prolong Pharmaceuticals
• Boston Pharmaceuticals

Key Questions Answered in this Report:

• What are the main factors driving the demand for synthetic blood substitute market?
• What are the major patents filed by the companies active in synthetic blood substitute market?
• Who are the key players in the synthetic blood substitute market, and what are their respective market shares?
• What are the strategies adopted by the key companies to gain a competitive edge in synthetic blood substitute market?
• What is the futuristic outlook for the synthetic blood substitute market in terms of growth potential?
• What is the current estimation of the synthetic blood substitute market, and what growth trajectory is projected from 2024 to 2034?
• Which application, and product segment is expected to lead the market over the forecast period (2024-2034)?
• Which regions demonstrate the highest adoption rates for synthetic blood substitute market, and what factors contribute to their leadership?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

• 1.1 Trends: Current and Future Impact Assessment
  • 1.1.1 Increasing Demand for Blood Transfusions due to Rising Trauma and Chronic Diseases
  • 1.1.2 Advancement in Stem Cell Technology and Regenerative Medicine
  • 1.1.3 Integration with Advanced Diagnostics and Monitoring
• 1.2 Supply Chain Overview
  • 1.2.1 Value Chain Analysis
  • 1.2.2 Pricing Forecast
• 1.3 R&D Review
  • 1.3.1 Patent Filing Trend by Country, by Company
• 1.4 Regulatory Landscape
• 1.5 Stakeholder Analysis
  • 1.5.1 Use Case
  • 1.5.2 End User and Buying Criteria
• 1.6 Impact Analysis for Key Global Events
• 1.7 Market Dynamics Overview
  • 1.7.1 Market Drivers
  • 1.7.2 Market Restraints
  • 1.7.3 Market Opportunities

2. Synthetic Blood Substitute Market (by Application)

• 2.1 Application Segmentation
• 2.2 Application Summary
• 2.3 Synthetic Blood Substitute Market (by Application)
  • 2.3.1 Cardiovascular Diseases
  • 2.3.2 Malignant Neoplasma
  • 2.3.3 Injuries
  • 2.3.4 Neonatal Conditions
  • 2.3.5 Organ Transplant
  • 2.3.6 Maternal Condition
  • 2.3.7 Others
• 2.4 Synthetic Blood Substitute Market (by End-use)
  • 2.4.1 Hospitals
  • 2.4.2 Ambulatory Surgical Centers
  • 2.4.3 Military and Defense
  • 2.4.4 Research Laboratories
  • 2.4.5 Emergency Services
  • 2.4.6 Others

3. Synthetic Blood Substitute Market (by Product)

• 3.1 Product Segmentation
• 3.2 Product Summary
• 3.3 Synthetic Blood Substitute Market (by Product)
  • 3.3.1 Hemoglobin-Based Oxygen Carriers (HBOCs)
  • 3.3.2 Perfluorocarbon Emulsions (PFCs)
  • 3.3.3 Stem Cell-Derived Red Blood Cells
  • 3.3.4 Others
• 3.4 Synthetic Blood Substitute Market (by Source)
  • 3.4.1 Human Blood
  • 3.4.2 Microorganism Based Recombinant HB
  • 3.4.3 Synthetic Polymers
  • 3.4.4 Stem Cells
  • 3.4.5 Others
• 3.5 Synthetic Blood Substitute Market (by Type)
  • 3.5.1 Red Blood Cell Substitutes
  • 3.5.2 Platelet Substitutes
  • 3.5.3 Plasma Substitutes
• 3.6 Synthetic Blood Substitute Market (by Configuration)
  • 3.6.1 Injectable Solutions
  • 3.6.2 Powdered Forms
  • 3.6.3 Infusion Bags
  • 3.6.4 Capsules and Tablets
  • 3.6.5 Others

4. Synthetic Blood Substitute Market (by Region)

• 4.1 Synthetic Blood Substitute Market (by Region)
• 4.2 North America
  • 4.2.1 Regional Overview
  • 4.2.2 Driving Factors for Market Growth
  • 4.2.3 Factors Challenging the Market
  • 4.2.4 Application
  • 4.2.5 Product
  • 4.2.6 North America Synthetic Blood Substitute Market (by Country)
    • 4.2.6.1 U.S.
      • 4.2.6.1.1 Market by Application
      • 4.2.6.1.2 Market by Product
    • 4.2.6.2 Canada
      • 4.2.6.2.1 Market by Application
      • 4.2.6.2.2 Market by Product
    • 4.2.6.3 Mexico
      • 4.2.6.3.1 Market by Application
      • 4.2.6.3.2 Market by Product
• 4.3 Europe
  • 4.3.1 Regional Overview
  • 4.3.2 Driving Factors for Market Growth
  • 4.3.3 Factors Challenging the Market
  • 4.3.4 Application
  • 4.3.5 Product
  • 4.3.6 Europe Synthetic Blood Substitute Market (by Country)
    • 4.3.6.1 Germany
      • 4.3.6.1.1 Market by Application
      • 4.3.6.1.2 Market by Product
    • 4.3.6.2 France
      • 4.3.6.2.1 Market by Application
      • 4.3.6.2.2 Market by Product
    • 4.3.6.3 U.K.
      • 4.3.6.3.1 Market by Application
      • 4.3.6.3.2 Market by Product
    • 4.3.6.4 Italy
      • 4.3.6.4.1 Market by Application
      • 4.3.6.4.2 Market by Product
    • 4.3.6.5 Rest-of-Europe
      • 4.3.6.5.1 Market by Application
      • 4.3.6.5.2 Market by Product
• 4.4 Asia-Pacific
  • 4.4.1 Regional Overview
  • 4.4.2 Driving Factors for Market Growth
  • 4.4.3 Factors Challenging the Market
  • 4.4.4 Application
  • 4.4.5 Product
  • 4.4.6 Asia-Pacific Synthetic Blood Substitute Market (by Country)
    • 4.4.6.1 China
      • 4.4.6.1.1 Market by Application
      • 4.4.6.1.2 Market by Product
    • 4.4.6.2 Japan
      • 4.4.6.2.1 Market by Application
      • 4.4.6.2.2 Market by Product
    • 4.4.6.3 India
      • 4.4.6.3.1 Market by Application
      • 4.4.6.3.2 Market by Product
    • 4.4.6.4 South Korea
      • 4.4.6.4.1 Market by Application
      • 4.4.6.4.2 Market by Product
    • 4.4.6.5 Rest-of-Asia-Pacific
      • 4.4.6.5.1 Market by Application
      • 4.4.6.5.2 Market by Product
• 4.5 Rest-of-the-World
  • 4.5.1 Regional Overview
  • 4.5.2 Driving Factors for Market Growth
  • 4.5.3 Factors Challenging the Market
  • 4.5.4 Application
  • 4.5.5 Product
  • 4.5.6 Rest-of-the-World Synthetic Blood Substitute Market (by Region)
    • 4.5.6.1 South America
      • 4.5.6.1.1 Market by Application
      • 4.5.6.1.2 Market by Product
    • 4.5.6.2 Middle East and Africa
      • 4.5.6.2.1 Market by Application
      • 4.5.6.2.2 Market by Product

5. Companies Profiled

• 5.1 Next Frontiers
• 5.2 Geographic Assessment
• 5.3 Company Profiles
  • 5.3.1 Aurum Biosciences
    • 5.3.1.1 Overview
    • 5.3.1.2 Top Products/Product Portfolio
    • 5.3.1.3 Top Competitors
    • 5.3.1.4 Target Customers
    • 5.3.1.5 Key Personnel
    • 5.3.1.6 Analyst View
    • 5.3.1.7 Market Share
  • 5.3.2 HEMARINA
    • 5.3.2.1 Overview
    • 5.3.2.2 Top Products/Product Portfolio
    • 5.3.2.3 Top Competitors
    • 5.3.2.4 Target Customers
    • 5.3.2.5 Key Personnel
    • 5.3.2.6 Analyst View
    • 5.3.2.7 Market Share
  • 5.3.3 Hemoglobin Oxygen Therapeutics LLC
    • 5.3.3.1 Overview
    • 5.3.3.2 Top Products/Product Portfolio
    • 5.3.3.3 Top Competitors
    • 5.3.3.4 Target Customers
    • 5.3.3.5 Key Personnel
    • 5.3.3.6 Analyst View
    • 5.3.3.7 Market Share
  • 5.3.4 KaloCyte, Inc.
    • 5.3.4.1 Overview
    • 5.3.4.2 Top Products/Product Portfolio
    • 5.3.4.3 Top Competitors
    • 5.3.4.4 Target Customers
    • 5.3.4.5 Key Personnel
    • 5.3.4.6 Analyst View
    • 5.3.4.7 Market Share
  • 5.3.5 Spheritech Ltd
    • 5.3.5.1 Overview
    • 5.3.5.2 Top Products/Product Portfolio
    • 5.3.5.3 Top Competitors
    • 5.3.5.4 Target Customers
    • 5.3.5.5 Key Personnel
    • 5.3.5.6 Analyst View
    • 5.3.5.7 Market Share
  • 5.3.6 VisusMed Medical Center
    • 5.3.6.1 Overview
    • 5.3.6.2 Top Products/Product Portfolio
    • 5.3.6.3 Top Competitors
    • 5.3.6.4 Target Customers
    • 5.3.6.5 Key Personnel
    • 5.3.6.6 Analyst View
    • 5.3.6.7 Market Share
  • 5.3.7 OPKO Health, Inc.
    • 5.3.7.1 Overview
    • 5.3.7.2 Top Products/Product Portfolio
    • 5.3.7.3 Top Competitors
    • 5.3.7.4 Target Customers
    • 5.3.7.5 Key Personnel
    • 5.3.7.6 Analyst View
    • 5.3.7.7 Market Share
  • 5.3.8 NuvOx Pharma
    • 5.3.8.1 Overview
    • 5.3.8.2 Top Products/Product Portfolio
    • 5.3.8.3 Top Competitors
    • 5.3.8.4 Target Customers
    • 5.3.8.5 Key Personnel
    • 5.3.8.6 Analyst View
    • 5.3.8.7 Market Share
  • 5.3.9 Prolong Pharmaceuticals
    • 5.3.9.1 Overview
    • 5.3.9.2 Top Products/Product Portfolio
    • 5.3.9.3 Top Competitors
    • 5.3.9.4 Target Customers
    • 5.3.9.5 Key Personnel
    • 5.3.9.6 Analyst View
    • 5.3.9.7 Market Share
  • 5.3.10 Boston Pharmaceuticals
    • 5.3.10.1 Overview
    • 5.3.10.2 Top Products/Product Portfolio
    • 5.3.10.3 Top Competitors
    • 5.3.10.4 Target Customers
    • 5.3.10.5 Key Personnel
    • 5.3.10.6 Analyst View
    • 5.3.10.7 Market Share
  • 5.3.11 ATPL
    • 5.3.11.1 Overview
    • 5.3.11.2 Top Products/Product Portfolio
    • 5.3.11.3 Top Competitors
    • 5.3.11.4 Target Customers
    • 5.3.11.5 Key Personnel
    • 5.3.11.6 Analyst View
    • 5.3.11.7 Market Share
  • 5.3.12 Baxter
    • 5.3.12.1 Overview
    • 5.3.12.2 Top Products/Product Portfolio
    • 5.3.12.3 Top Competitors
    • 5.3.12.4 Target Customers
    • 5.3.12.5 Key Personnel
    • 5.3.12.6 Analyst View
    • 5.3.12.7 Market Share
  • 5.3.13 Biopharma corp
    • 5.3.13.1 Overview
    • 5.3.13.2 Top Products/Product Portfolio
    • 5.3.13.3 Top Competitors
    • 5.3.13.4 Target Customers
    • 5.3.13.5 Key Personnel
    • 5.3.13.6 Analyst View
    • 5.3.13.7 Market Share
  • 5.3.14 NORTHFIELD LABORATORIES INC.
    • 5.3.14.1 Overview
    • 5.3.14.2 Top Products/Product Portfolio
    • 5.3.14.3 Top Competitors
    • 5.3.14.4 Target Customers
    • 5.3.14.5 Key Personnel
    • 5.3.14.6 Analyst View
    • 5.3.14.7 Market Share
  • 5.3.15 Alliance Pharma PLC
    • 5.3.15.1 Overview
    • 5.3.15.2 Top Products/Product Portfolio
    • 5.3.15.3 Top Competitors
    • 5.3.15.4 Target Customers
    • 5.3.15.5 Key Personnel
    • 5.3.15.6 Analyst View
    • 5.3.15.7 Market Share
  • 5.3.16 Other Key Companies

6. Research Methodology

관련자료